Search all trials

Find therapies in clinical trials near you – page 8

Search by disease and location to discover available clinical trials matching your criteria. Updated every day from authoritative EU registries.

recruiting: 3 961
countries: 28
conditions: 2 103

3 961 trials recruiting28 European countries2 103 conditions coveredUpdated today

Quick filters

Study on Bortezomib and Drug Combination for Children with High-Risk Relapsed Acute Lymphoblastic Leukemia (ALL)

Recruiting

Registered drugNo placebo

Study on Bortezomib and Drug Combination for Children with High-Risk Relapsed Acute Lymphoblastic Leukemia (ALL)

Registered drugNo placebo

Spain

Participants:0–17 years
Substances:Bortezomib

Contact Research Centre

Bronchopulmonary dysplasia

Recruiting

Investigational

Study to Test if Zelpultide Alfa Helps Prevent Lung Disease in High-Risk Premature Babies

Investigational

Spain

Participants:0–17 years
Substances:Recombinant Human Surfactant Protein-D

Contact Research Centre

Acute lymphocytic leukaemia+4

Recruiting

Registered drugNo placebo

Study of Ruxolitinib and Venetoclax for Children with Relapsed or Refractory Leukemia or Lymphoma with IL-7R/JAK-STAT Pathway Mutations

Registered drugNo placebo

Spain

Participants:0–17 years · 18–64 years
Substances:Ruxolitinib

Contact Research Centre

Neuroblastoma+1

Recruiting

Registered drugNo placebo

Study of ABTL0812, Irinotecan, and Temozolomide for Children with Relapsed or Refractory Neuroblastoma and Other Solid Tumors

Registered drugNo placebo

Spain

Participants:0–17 years · 18–64 years
Substances:Irinotecan

Contact Research Centre

Acute myeloid leukaemia

Recruiting

Registered drugNo placebo

Study on Treating Acute Myeloid Leukemia in Children and Adolescents Using Daunorubicin, Mitoxantrone, and a Drug Combination

Registered drugNo placebo

Spain

Participants:0–17 years · 18–64 years
Substances:Cytarabine

Contact Research Centre

Ependymoma

Recruiting

Registered drugNo placebo

Study on Ependymoma Treatment in Children, Adolescents, and Young Adults Using Cisplatin, Cyclophosphamide, Etoposide, and a Drug Combination

Registered drugNo placebo

Spain

Participants:0–17 years · 18–64 years
Substances:Cisplatin

Contact Research Centre

Rhabdomyosarcoma

Recruiting

Registered drugNo placebo

Study of drug combinations including irinotecan, ifosfamide, vincristine, dactinomycin, regorafenib and other agents for children and adults with rhabdomyosarcoma

Registered drugNo placebo

Spain

Participants:0–17 years · 18–64 years · 65+ years
Substances:Cyclophosphamide

Contact Research Centre

Acute myeloid leukaemia+3

Recruiting

Registered drugNo placebo

Study on Ponatinib for Treating Recurrent or Refractory Leukemias and Solid Tumors in Children

Registered drugNo placebo

Spain

Participants:0–17 years
Substances:Ponatinib

Contact Research Centre

Myasthenia gravis

Recruiting

Registered drugNo placebo

Study on the Long-term Safety of Efgartigimod for Children with Generalized Myasthenia Gravis

Registered drugNo placebo

Spain

Participants:0–17 years
Substances:Efgartigimod Alfa

Contact Research Centre

Neoplasm

Recruiting

InvestigationalNo placebo

Study on Repotrectinib for Children and Young Adults with Advanced Solid Tumors with ALK, ROS1, or NTRK1-3 Alterations

InvestigationalNo placebo

Spain

Participants:0–17 years · 18–64 years
Substances:Repotrectinib

Contact Research Centre

B-cell lymphoma+2

Recruiting

Registered drugNo placebo

Long-Term Follow-Up Study for Patients Treated with CAR T-Cell Therapy Using PHE885, YTB323, and Tisagenlecleucel

Registered drugNo placebo

Spain

Participants:0–17 years · 18–64 years · 65+ years
Substances:Tisagenlecleucel

Contact Research Centre

Still's disease

Recruiting

Investigational

Study of apremilast compared to placebo in children aged 5-17 years with juvenile psoriatic arthritis

Investigational

Spain

Participants:0–17 years
Substances:Apremilast

Contact Research Centre

Find therapies in clinical trials near you – page 8

329 trials match your criteria

Study on Bortezomib and Drug Combination for Children with High-Risk Relapsed Acute Lymphoblastic Leukemia (ALL)

Study on Bortezomib and Drug Combination for Children with High-Risk Relapsed Acute Lymphoblastic Leukemia (ALL)

Bronchopulmonary dysplasia

Study to Test if Zelpultide Alfa Helps Prevent Lung Disease in High-Risk Premature Babies

Acute lymphocytic leukaemia+4

Study of Ruxolitinib and Venetoclax for Children with Relapsed or Refractory Leukemia or Lymphoma with IL-7R/JAK-STAT Pathway Mutations

Neuroblastoma+1

Study of ABTL0812, Irinotecan, and Temozolomide for Children with Relapsed or Refractory Neuroblastoma and Other Solid Tumors

Acute myeloid leukaemia

Study on Treating Acute Myeloid Leukemia in Children and Adolescents Using Daunorubicin, Mitoxantrone, and a Drug Combination

Ependymoma

Study on Ependymoma Treatment in Children, Adolescents, and Young Adults Using Cisplatin, Cyclophosphamide, Etoposide, and a Drug Combination

Rhabdomyosarcoma

Study of drug combinations including irinotecan, ifosfamide, vincristine, dactinomycin, regorafenib and other agents for children and adults with rhabdomyosarcoma

Acute myeloid leukaemia+3

Study on Ponatinib for Treating Recurrent or Refractory Leukemias and Solid Tumors in Children

Myasthenia gravis

Study on the Long-term Safety of Efgartigimod for Children with Generalized Myasthenia Gravis

Neoplasm

Study on Repotrectinib for Children and Young Adults with Advanced Solid Tumors with ALK, ROS1, or NTRK1-3 Alterations

B-cell lymphoma+2

Long-Term Follow-Up Study for Patients Treated with CAR T-Cell Therapy Using PHE885, YTB323, and Tisagenlecleucel

Still's disease

Study of apremilast compared to placebo in children aged 5-17 years with juvenile psoriatic arthritis

Explore other searches

Vaccine trials

Paediatric trials · ages 0–17

Healthy volunteers

Helpful resources

How applying through us works

What happens after you apply

Guides for patients and volunteers

Search filters

Prefer not to search? Our Concierge searches the trials for you.